Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other
From Akros SCHK HK-U.S. Tech 100 Index (ASHUSTC)
5/8/2026, 12:00:00 AM
The sNDA for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab is expected to be accepted for review by China's NMPA; this regulatory progress is estimated to have a 5% price impact expected.
Korean Translation
비소세포폐암 치료를 위한 sac-TMT 병용 요법의 sNDA 심사 접수가 예상되며, 이는 주요 규제 마일스톤 달성으로 약 5%의 주가 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Earnings Release
Microsoft is scheduled to report its Q4 and full-year fiscal 2026 earnings results on 2026-07-28, with analysts forecasting EPS around $4.24-$4.33. High importance is estimated due to typical 10% price volatility following earnings scheduled.
7/28/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Other
AMD's 'Advancing AI 2026' event to detail future AI product roadmaps on July 23, 2026 is expected to have a 5% price impact scheduled.
7/23/2026, 12:00:00 AM
Amphenol Corp (APH) · Earnings Release
Next quarterly earnings release for Q2 2026 is a routine administrative event with low expected impact, scheduled.
7/22/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Earnings Release
Q2 2026 earnings release scheduled for 2026-07-22; low importance estimated as earnings typically cause moderate volatility, expected.
7/22/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM